Exclusivity Parking Still Possible Under Teva Ruling
The U.S. Food and Drug Administration's finding this year that Teva Parenteral Medicines Inc. would not have to renounce its exclusivity window for its generic granisetron cast light on certain holes...To view the full article, register now.
Already a subscriber? Click here to view full article